Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.

BACKGROUND: There are no U.S. Food and Drug Administration (FDA)-approved medications for the treatment of anorexia nervosa (AN). Various medication classes have been evaluated for benefits in this population, including antipsychotics. Studies focused on use of antipsychotics for assistance with weight restoration in AN produced conflicting results. While current evidence does not suggest that antipsychotic medications can be generally recommended for persons with AN, some individuals might benefit from an antipsychotic medication for anxiety, mood, and the cognitive distortions that accompany the illness. It is well-established that atypical antipsychotics can cause weight gain when taken by other psychiatric populations. This published data can understandably limit the willingness of persons with AN to trial these medications. Given the conflicting results of studies examining antipsychotic-related weight gain in AN, it is currently hypothesized that individuals with extreme anorexia nervosa, restricting type, do not experience the weight gain seen in other psychiatric populations utilizing atypical antipsychotics. METHODS: Two hundred seventy-six individuals with extreme AN were enrolled in this retrospective, case-control study between April 1, 2016 and June 30, 2022 utilizing study-specific inclusion and exclusion criteria. Clinical and demographic data, including use of atypical antipsychotics and weights, were retrospectively obtained from chart review. Variables were assessed for normality using univariate statistics. Continuous variables were described using means (M) and standard deviations (SD) or medians and interquartile ranges (IQR) based on normality. Differences in weight gain between cohorts was ascertained via independent samples t-test. P values of < 0.05 were considered statistically significant, and all analyses were completed using SAS Enterprise Guide software version 7.1 (SAS Institute, Cary, NC) and R version 4.3.1 (R Core Team, 2023). RESULTS: Use of antipsychotics in this population of individuals with extreme AN did not impact the rate of weight gain (M: 1.7 kg/week, SD: 0.9 and 0.8, for cases and controls respectively). CONCLUSIONS: Weight gain is often cited by individuals with AN as a feared side effect of antipsychotic medications. In this study, there was no difference in weight trends for individuals taking atypical antipsychotic medications during the refeeding process compared with individuals who were not.

While antipsychotics are not FDA-approved for, and cannot be generally recommended for, people diagnosed with anorexia nervosa, there are those who may derive benefit from utilizing these medications for their rigid and circular thoughts associated with the disorder, or for their mood and anxiety symptoms. Yet, many such individuals are hesitant to take these medications due to their fear of the weight gain which has been associated with their usage. In this study population of individuals suffering from extreme AN, who were undergoing refeeding and weight restoration, there was no impact on weight gain trends in individuals taking atypical antipsychotics compared to individuals who were not taking these medications.

Emergency room presentations of people with anorexia nervosa.

People with anorexia nervosa (AN) tend to shy away from engaging in typical primary care provider relationships in order to avoid detection. Therefore, they may seek care for their medical concerns through a local emergency department (ED). Inherently, AN is associated with a litany of medical complications, which become more prevalent as the severity of their eating disorder increases. Notwithstanding the typical young age at the onset of AN, no body system is immune to these medical complications. Thus, ED providers may need to pursue a medical diagnosis in order to explain presenting symptoms in people with AN. In addition to the medical issues, AN is also a serious mental illness with high mortality rates, including deaths by suicide. Therefore, ED providers also need to be familiar with relevant mental health issues for these people.

People with anorexia nervosa frequent emergency departments to obtain their medical care. It is thus important for emergency department personnel to be familiar with this increasingly common and serious disorder. As opposed to most other mental illnesses, anorexia nervosa is associated with many dangerous medical complications, which become more problematic as the malnutrition and weight loss become more severe. All body systems are adversely affected. The mortality rate of anorexia nervosa is the second highest of all mental disorders, with medical complications and suicide being the top two causes of death. Mandated medical care may occasionally be required to obtain ongoing treatment for people with anorexia nervosa when they present to the emergency department with severe malnutrition and other emergent complications.

Continuous 2D control via state-machine triggered by endogenous sensory discrimination and a fast brain switch.

OBJECTIVE: Brain computer interfacing (BCI) is a promising method to control assistive systems for patients with severe disabilities. Recently, we have presented a novel BCI approach that combines an electrotactile menu and a brain switch, which allows the user to trigger many commands robustly and efficiently. However, the commands are timed to periodic tactile cues and this may challenge online control. In the present study, therefore, we implemented and evaluated a novel approach for online closed-loop control using the proposed BCI. APPROACH: Eleven healthy subjects used the novel method to move a cursor in a 2D space. To assure robust control with properly timed commands, the BCI was integrated within a state machine allowing the subject to start the cursor movement in the selected direction and asynchronously stop the cursor. The brain switch was controlled using motor execution (ME) or imagery (MI) and the menu implemented four (straight movements) or eight commands (straight and diagonal movements). MAIN RESULTS: The results showed a high completion rate of a target hitting task (~97% and ~92% for ME and MI, respectively), with a small number of collisions, when four-channel control was used. There was no significant difference in outcome measures between MI and ME, and performance was similar for four and eight commands. SIGNIFICANCE: These results demonstrate that the novel state-based scheme driven by a robust BCI can be successfully utilized for online control. Therefore, it can be an attractive solution for providing the user an online-control interface with many commands, which is difficult to achieve using classic BCI solutions.

Sero-negative celiac disease with dermatitis herpetiformes: a case report.

INTRODUCTION: We report a case of sero-negative celiac disease in Pakistan. CASE PRESENTATION: A 20-year-old female presented with papulovesicular rash for 15 years, diarrhea for 8 years, spasms of hands and twitching of face for 4-5 months. She had mild anemia, low vitamin-D3 and serum calcium. On exclusion of other causes of malabsorption, anti-tissue transglutaminase antibodies (immunoglobulin-A & immunoglobulin-G), anti-endomysial antibodies, total immunoglobulin-A levels and skin biopsy were performed, which were normal. Intestinal biopsy revealed subtotal villous atrophy. Patient was prescribed gluten-free diet, to which she responded with alleviation of symptoms. CONCLUSION: Negative serology should not rule out celiac disease; intestinal biopsy should be performed if there is strong clinical suspicion.